Mechanistic basis and clinical relevance of the role of transforming growth factor-β in cancer

Cancer Biology and Medicine

Volumn 12, Issue 4, 2015, Pages 385-393

  Lin, Run Long ^a   Zhao, Lu Jun ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Neoplasms; Prognosis; Therapeutics; Transforming growth factor (TGF )

Indexed keywords

CYTOSTATIC AGENT; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL INVASION; DISTANT METASTASIS; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; IN VITRO STUDY; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; NEGATIVE FEEDBACK; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STAGING; SYSTEMATIC REVIEW; TUMOR INVASION; TUMOR MICROENVIRONMENT;

EID: 84954317176     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.7497/j.issn.2095-3941.2015.0015     Document Type: Review

References (74)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. Massagué J. TGFbeta in Cancer. Cell 2008;134:215-230.
3. Attisano L, Cárcamo J, Ventura F, Weis FM, Massagué J, Wrana JL. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993;75:671-680.
4. Massagué J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000;1:169-178.
5. Massagué J. TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-791.
6. Mu Y, Gudey SK, Landstrom M. Non-Smad signaling pathways. Cell Tissue Res 2012;347:11-20.
7. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009;19:128-139.
8. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF- beta-induced cell cycle arrest. Nature 1994;371:257-261.
9. Li CY, Suardet L, Little JB. Potential role of WAF1/Cip1/p21 as a mediator of TGF-beta cytoinhibitory effect. J Biol Chem 1995;270:4971-4974.
10. Reynisdóttir I, Massagué J. The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev 1997;11:492-503.
11. Vijayachandra K, Higgins W, Lee J, Glick A. Induction of p16ink4a and p19ARF by TGFbeta1 contributes to growth arrest and senescence response in mouse keratinocytes. Mol Carcinog 2009;48:181-186.
12. Bierie B, Moses HL. Gain or loss of TGFbeta signaling in mammary carcinoma cells can promote metastasis. Cell Cycle 2009;8:3319-3327.
13. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 2001;3:392-399.
14. Warner BJ, Blain SW, Seoane J, Massagué J. Myc downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G(1) arrest pathway. Mol Cell Biol 1999;19:5913-5922.
15. Chen CR, Kang Y, Massague J. Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci U S A 2001;98:992-999.
16. Kang Y, Chen CR, Massague J. A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell 2003;11:915-926.
17. Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 2000;407:592-598.
18. Perlman R, Schiemann WP, Brooks MW, Lodish HF, Weinberg RA. TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat Cell Biol 2001;3:708-714.
19. Jang CW, Chen CH, Chen CC, Chen JY, Su YH, Chen RH. TGF- beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nat Cell Biol 2002;4:51-58.
20. Xu F, Sun W, Li P, Chen J, Zhu D, Sun X, et al. Specificity protein 1 transcription factor regulates human ARTS promoter activity through multiple binding sites. PLoS One 2015;10:e0120072.
21. Barrack ER. TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 1997;31:61-70.
22. Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, Aakre M, et al. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res 2008;68:1809-1819.
23. de Carvalho F, Colleoni GW, Almeida MS, Carvalho AL, Vettore AL. TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. Int J Cancer 2009;125:1985-1991.
24. Levy L, Hill CS. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006;17:41-58.
25. Tarasewicz E, Jeruss JS. Phospho-specific Smad3 signaling: impact on breast oncogenesis. Cell Cycle 2012;11:2443-2451.
26. Boye A, Kan H, Wu C, Jiang Y, Yang X, He S, et al. MAPK inhibitors differently modulate TGF-beta/Smad signaling in HepG2 cells. Tumour Biol 2015. [Epub ahead of print].
27. Handra-Luca A, Olschwang S, Flejou JF. SMAD4 protein expression and cell proliferation in colorectal adenocarcinomas. Virchows Arch 2011;459:511-519.
28. Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009;15:4674-4679.
29. D'Inzeo S, Nicolussi A, Donini CF, Zani M, Mancini P, Nardi F, et al. A novel human Smad4 mutation is involved in papillary thyroid carcinoma progression. Endocr Relat Cancer 2012;19:39-55.
30. Luo L, Li N, Lv N, Huang D. SMAD7: a timer of tumor progression targeting TGF-beta signaling. Tumour Biol 2014;35:8379-8385.
31. White RA, Malkoski SP, Wang XJ. TGFbeta signaling in head and neck squamous cell carcinoma. Oncogene 2010;29:5437-5446.
32. Chatterjee R, Mitra A. An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer. Int Immunopharmacol 2015;24:335-345.
33. Soufla G, Sifakis S, Porichis F, Spandidos DA. Prognostic value of tgfb1 protein in endometrioid adenocarcinoma. Eur J Clin Invest 2013;43:79-90.
34. Weidenaar AC, ter Elst A, Kampen KR, Meeuwsen-de Boer TG, de Jonge HJ, Scherpen FJ, et al. Stromal interaction essential for vascular endothelial growth factor A-induced tumour growth via transforming growth factor-beta signalling. Br J Cancer 2011;105:1856-1863.
35. Zakrzewski PK, Cygankiewicz AI, Mokrosiński J, Nowacka-Zawisza M, Semczuk A, Rechberger T, et al. Expression of endoglin in primary endometrial cancer. Oncology 2011;81:243-250.
36. Lin H, Huang CC, Ou YC, Huang EY, Changchien CC, Tseng CW, et al. High immunohistochemical expression of TGF-beta1 predicts a poor prognosis in cervical cancer patients who harbor enriched endoglin microvessel density. Int J Gynecol Pathol 2012;31:482-489.
37. Pardali E, van der Schaft DW, Wiercinska E, Gorter A, Hogendoorn PC, Griffioen AW, et al. Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene 2011;30:334-345.
38. Bellone G, Gramigni C, Vizio B, Mauri FA, Prati A, Solerio D, et al. Abnormal expression of Endoglin and its receptor complex (TGF-beta1 and TGF-beta receptor II) as early angiogenic switch indicator in premalignant lesions of the colon mucosa. Int J Oncol 2010;37:1153-1165.
39. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-458.
40. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
41. Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, et al. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF- beta. J Immunol 2007;178:2883-2892.
42. Lin GH, Wang J, Li SH, Wang J, Xu L, Li SP. Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma. Chin J Cancer 2010;29:403-407.
43. Lu X, Liu J, Li H, Li W, Wang X, Ma J, et al. Conversion of intratumoral regulatory T cells by human gastric cancer cells is dependent on transforming growth factor-beta1. J Surg Oncol 2011;104:571-577.
44. Luo H, Hao Y, Tang B, Zeng D, Shi Y, Yu P. Mouse forestomach carcinoma cells immunosuppress macrophages through transforming growth factor-beta1. Mol Med Rep 2012;5:988-992.
45. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF- beta: "N1" versus "N2" TAN. Cancer Cell 2009;16:183-194.
46. Chalmin F, Mignot G, Bruchard M, Chevriaux A, Végran F, Hichami A, et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 2012;36:362-373.
47. Katsuno Y, Lamouille S, Derynck R. TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 2013;25:76-84.
48. Cheng JC, Auersperg N, Leung PC. TGF-beta induces serous borderline ovarian tumor cell invasion by activating EMT but triggers apoptosis in low-grade serous ovarian carcinoma cells. PLoS One 2012;7:e42436.
49. Pino MS, Kikuchi H, Zeng M, Herraiz MT, Sperduti I, Berger D, et al. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology 2010;138:1406-1417.
50. Zhao L, Ji W, Zhang L, Ou G, Feng Q, Zhou Z, et al. Changes of circulating transforming growth factor-beta1 level during radiation therapy are correlated with the prognosis of locally advanced non- small cell lung cancer. J Thorac Oncol 2010;5:521-525.
51. Hardee ME, Marciscano AE, Medina-Ramirez CM, Zagzag D, Narayana A, Lonning SM, et al. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-beta. Cancer Res 2012;72:4119-4129.
52. Tas F, Karabulut S, Serilmez M, Ciftci R, Duranyildiz D. Clinical significance of serum transforming growth factor-beta 1 (TGF- beta1) levels in patients with epithelial ovarian cancer. Tumour Biol 2014;35:3611-3616.
53. Yang SD, Sun RC, Mu HJ, Xu ZQ, Zhou ZY. The expression and clinical significance of TGF-beta1 and MMP2 in human renal clear cell carcinoma. Int J Surg Pathol 2010;18:85-93.
54. Malaponte G, Zacchia A, Bevelacqua Y, Marconi A, Perrotta R, Mazzarino MC, et al. Co-regulated expression of matrix metalloproteinase-2 and transforming growth factor-beta in melanoma development and progression. Oncol Rep 2010;24:81-87.
55. Chen Y, Zhang W, Geng N, Tian K, Jack Windsor L. MMPs, TIMP-2, and TGF-beta1 in the cancerization of oral lichen planus. Head Neck 2008;30:1237-1245.
56. Robson H, Anderson E, James RD, Schofield PF. Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 1996;74:753-758.
57. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, et al. The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 1999;86:1455-1462.
58. Boldrini L, Calcinai A, Samaritani E, Pistolesi F, Mussi A, Lucchi M, et al. Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2- mediated neovascularization. Br J Cancer 2000;83:480-486.
59. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 2001;91:964-971.
60. Hashimoto K, Nio Y, Sumi S, Toga T, Omori H, Itakura M, et al. Correlation between TGF-beta1 and p21 (WAF1/CIP1) expression and prognosis in resectable invasive ductal carcinoma of the pancreas. Pancreas 2001;22:341-347.
61. Logullo AF, Nonogaki S, Miguel RE, Kowalski LP, Nishimoto IN, Pasini FS, et al. Transforming growth factor beta1 (TGFbeta1) expression in head and neck squamous cell carcinoma patients as related to prognosis. J Oral Pathol Med 2003;32:139-145.
62. Fukuchi M, Miyazaki T, Fukai Y, Nakajima M, Sohda M, Masuda N, et al. Plasma level of transforming growth factor beta1 measured from the azygos vein predicts prognosis in patients with esophageal cancer. Clin Cancer Res 2004;10:2738-2741.
63. Okumoto K, Hattori E, Tamura K, Kiso S, Watanabe H, Saito K, et al. Possible contribution of circulating transforming growth factor- beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int 2004;24:21-28.
64. von Rahden BH, Stein HJ, Feith M, Pühringer F, Theisen J, Siewert JR, et al. Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis. Mol Carcinog 2006;45:786-794.
65. Reis ST, Pontes-Júnior J, Antunes AA, Sousa-Canavez JM, Abe DK, Cruz JA, et al. Tgf-beta1 expression as a biomarker of poor prognosis in prostate cancer. Clinics (Sao Paulo) 2011;66:1143-1147.
66. Valkov A, Sorbye SW, Kilvaer TK, Donnem T, Smeland E, Bremnes RM, et al. The prognostic impact of TGF-beta1, fascin, NF-kappaB and PKC-zeta expression in soft tissue sarcomas. PLoS One 2011;6:e17507.
67. Dave H, Shah M, Trivedi S, Shukla S. Prognostic utility of circulating transforming growth factor beta 1 in breast cancer patients. Int J Biol Markers 2012;27:53-59.
68. Fan DM, Wang XJ, He T, Wang Y, Zhou D, Kong GQ, et al. High expression of TGF-beta1 in the vaginal incisional margin predicts poor prognosis in patients with stage Ib-IIa cervical squamous cell carcinoma. Mol Biol Rep 2012;39:3925-3931.
69. Divella R, Daniele A, Savino E, Palma F, Bellizzi A, Giotta F, et al. Circulating levels of transforming growth factor-betaeta (TGF- beta) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer. Anticancer Res 2013;33:1491-1497.
70. Javle M, Li Y, Tan D, Dong X, Chang P, Kar S, et al. Biomarkers of TGF-beta signaling pathway and prognosis of pancreatic cancer. PLoS One 2014;9:e85942.
71. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 2011;13:132-142.
72. Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003;14:1816-1824.
73. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010;10:554-567.
74. Nam JS, Suchar AM, Kang MJ, Stuelten CH, Tang B, Michalowska AM, et al. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res 2006;66:6327-6335.